[144] Avidity Biosciences, Inc. SEC Filing
Form 144 summary for Avidity Biosciences (RNA): The filing notifies a proposed sale of 30,914 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $1,182,769.64, scheduled for 08/06/2025. The securities were acquired as Performance Stock Units from the issuer on 12/17/2024 (amount 30,914; date of payment listed as 12/17/2024; nature of payment: N/A). The filing reports "Nothing to Report" for securities sold in the past three months. Several filer identification and notice fields (CIK, submission contact name, date of notice) are blank or not provided in the document, limiting disclosure.
Form 144 summary per Avidity Biosciences (RNA): Il deposito segnala una proposta di vendita di 30,914 azioni ordinarie tramite Morgan Stanley Smith Barney LLC su NASDAQ con un valore di mercato complessivo di $1,182,769.64, prevista per il 08/06/2025. I titoli sono stati acquisiti come Performance Stock Units dall'emittente il 12/17/2024 (quantit脿 30,914; data di pagamento indicata: 12/17/2024; natura del pagamento: N/A). Il deposito riporta "Niente da segnalare" per titoli venduti negli ultimi tre mesi. Diversi campi identificativi e di notifica del dichiarante (CIK, nome del contatto per l'invio, data della notifica) risultano vuoti o non forniti nel documento, limitando la disclosure.
Resumen del Formulario 144 para Avidity Biosciences (RNA): La presentaci贸n notifica una propuesta de venta de 30,914 acciones ordinarias a trav茅s de Morgan Stanley Smith Barney LLC en NASDAQ con un valor de mercado agregado de $1,182,769.64, programada para el 08/06/2025. Los valores fueron adquiridos como Performance Stock Units del emisor el 12/17/2024 (cantidad 30,914; fecha de pago indicada: 12/17/2024; naturaleza del pago: N/A). La presentaci贸n informa "Nada que Reportar" respecto a valores vendidos en los 煤ltimos tres meses. Varios campos de identificaci贸n y notificaci贸n del declarante (CIK, nombre del contacto de env铆o, fecha del aviso) aparecen en blanco o no se proporcionan en el documento, lo que limita la divulgaci贸n.
Avidity Biosciences (RNA)鞐� 雽�頃� Form 144 鞖旍暯: 鞝滌稖靹滊電� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 齑� 鞁滌灔臧�旃� $1,182,769.64鞐� 頃措嫻頃橂姅 30,914 氤错喌欤�鞚� 毵り皝 鞓堨爼(鞓堨爼鞚�: 08/06/2025)鞚� 韱奠頃╇媹雼�. 頃措嫻 歃濌秾鞚� 氚滍枆鞚胳溂搿滊秬韯� Performance Stock Units鞙茧 12/17/2024鞐� 旆摑霅橃棃鞀惦媹雼�(靾橂焿 30,914; 歆�旮夓澕 旮办灛: 12/17/2024; 歆�旮� 靹标博: N/A). 鞝滌稖靹滊姅 歆�雮� 3臧滌洈 雮� 毵り皝霅� 歃濌秾鞐� 雽�頃� "氤搓碃頃� 靷暛 鞐嗢潓"鞚措澕瓿� 氤搓碃頃橁碃 鞛堨姷雼堧嫟. 氍胳劀鞐愳劀 氇囯獓 鞁犼碃鞚� 鞁濍硠 氚� 韱奠 頃(CIK, 鞝滌稖 鞐半澖觳� 鞚措, 韱奠鞚�)鞚� 牍勳柎 鞛堦卑雮� 鞝滉车霅橃 鞎婌晞 瓿奠嫓臧� 鞝滍暅霅╇媹雼�.
R茅sum茅 du Formulaire 144 pour Avidity Biosciences (RNA) : Le d茅p么t signale une proposition de vente de 30,914 actions ordinaires via Morgan Stanley Smith Barney LLC sur le NASDAQ, pour une valeur marchande totale de $1,182,769.64, pr茅vue pour le 08/06/2025. Les titres ont 茅t茅 acquis en tant que Performance Stock Units aupr猫s de l'茅metteur le 12/17/2024 (quantit茅 30,914 ; date de paiement indiqu茅e : 12/17/2024 ; nature du paiement : N/A). Le d茅p么t indique "Rien 脿 signaler" pour les titres vendus au cours des trois derniers mois. Plusieurs champs d'identification et de notification du d茅clarant (CIK, nom du contact de soumission, date de l'avis) sont vides ou non fournis dans le document, ce qui limite la divulgation.
Form-144-Zusammenfassung f眉r Avidity Biosciences (RNA): Die Einreichung meldet einen geplanten Verkauf von 30.914 Stammaktien 眉产别谤 Morgan Stanley Smith Barney LLC an der NASDAQ mit einem Gesamtmarktwert von $1,182,769.64, vorgesehen f眉r den 08/06/2025. Die Wertpapiere wurden am 12/17/2024 als Performance Stock Units vom Emittenten erworben (Anzahl 30,914; Zahlungstag angegeben: 12/17/2024; Art der Zahlung: N/A). Die Einreichung vermerkt "Nichts zu berichten" f眉r in den letzten drei Monaten verkaufte Wertpapiere. Mehrere Identifikations- und Benachrichtigungsfelder des Meldenden (CIK, Name des Einreichungskontakts, Datum der Mitteilung) sind im Dokument leer oder fehlen, was die Offenlegung einschr盲nkt.
- Proposed sale routed through a registered broker: Morgan Stanley Smith Barney LLC is named as the broker for the sale on NASDAQ.
- Securities were acquired as Performance Stock Units from the issuer on 12/17/2024, as disclosed in the filing.
- No securities sold in the past three months is explicitly stated: "Nothing to Report".
- Key filer identification fields are blank or not provided (Filer CIK, filer contact name and details are missing in the document).
- Date of notice is not provided in the filing, limiting clarity on timing of the disclosure.
- Limited disclosure reduces transparency, constraining investor ability to assess the seller's identity and the sale's context.
Insights
TL;DR: Form 144 discloses a proposed insider sale of 30,914 shares (~$1.18M) with limited filer identification, constraining impact assessment.
The filing documents a planned sale of 30,914 common shares via Morgan Stanley Smith Barney LLC on NASDAQ dated 08/06/2025 and shows these shares were acquired as Performance Stock Units on 12/17/2024. The aggregate market value is explicitly stated as $1,182,769.64. The form does not disclose filer CIK, contact name, or the date of notice, which reduces transparency and makes it difficult to assess timing, insider identity, or the sale's relative significance to shareholders.
TL;DR: PSU-derived shares are being offered for sale; missing filer and date fields weaken disclosure and investor transparency.
The notice confirms the securities were acquired from the issuer as Performance Stock Units on 12/17/2024 and that the broker handling the sale is Morgan Stanley Smith Barney LLC. The filing includes the required Rule 144 representation and indicates no sales in the prior three months. However, absent filer identification (CIK and submission contact) and an explicit date of notice, the document provides incomplete identification and timing context, which is a transparency concern under routine disclosure expectations.
Form 144 summary per Avidity Biosciences (RNA): Il deposito segnala una proposta di vendita di 30,914 azioni ordinarie tramite Morgan Stanley Smith Barney LLC su NASDAQ con un valore di mercato complessivo di $1,182,769.64, prevista per il 08/06/2025. I titoli sono stati acquisiti come Performance Stock Units dall'emittente il 12/17/2024 (quantit脿 30,914; data di pagamento indicata: 12/17/2024; natura del pagamento: N/A). Il deposito riporta "Niente da segnalare" per titoli venduti negli ultimi tre mesi. Diversi campi identificativi e di notifica del dichiarante (CIK, nome del contatto per l'invio, data della notifica) risultano vuoti o non forniti nel documento, limitando la disclosure.
Resumen del Formulario 144 para Avidity Biosciences (RNA): La presentaci贸n notifica una propuesta de venta de 30,914 acciones ordinarias a trav茅s de Morgan Stanley Smith Barney LLC en NASDAQ con un valor de mercado agregado de $1,182,769.64, programada para el 08/06/2025. Los valores fueron adquiridos como Performance Stock Units del emisor el 12/17/2024 (cantidad 30,914; fecha de pago indicada: 12/17/2024; naturaleza del pago: N/A). La presentaci贸n informa "Nada que Reportar" respecto a valores vendidos en los 煤ltimos tres meses. Varios campos de identificaci贸n y notificaci贸n del declarante (CIK, nombre del contacto de env铆o, fecha del aviso) aparecen en blanco o no se proporcionan en el documento, lo que limita la divulgaci贸n.
Avidity Biosciences (RNA)鞐� 雽�頃� Form 144 鞖旍暯: 鞝滌稖靹滊電� Morgan Stanley Smith Barney LLC毳� 韱淀暣 NASDAQ鞐愳劀 齑� 鞁滌灔臧�旃� $1,182,769.64鞐� 頃措嫻頃橂姅 30,914 氤错喌欤�鞚� 毵り皝 鞓堨爼(鞓堨爼鞚�: 08/06/2025)鞚� 韱奠頃╇媹雼�. 頃措嫻 歃濌秾鞚� 氚滍枆鞚胳溂搿滊秬韯� Performance Stock Units鞙茧 12/17/2024鞐� 旆摑霅橃棃鞀惦媹雼�(靾橂焿 30,914; 歆�旮夓澕 旮办灛: 12/17/2024; 歆�旮� 靹标博: N/A). 鞝滌稖靹滊姅 歆�雮� 3臧滌洈 雮� 毵り皝霅� 歃濌秾鞐� 雽�頃� "氤搓碃頃� 靷暛 鞐嗢潓"鞚措澕瓿� 氤搓碃頃橁碃 鞛堨姷雼堧嫟. 氍胳劀鞐愳劀 氇囯獓 鞁犼碃鞚� 鞁濍硠 氚� 韱奠 頃(CIK, 鞝滌稖 鞐半澖觳� 鞚措, 韱奠鞚�)鞚� 牍勳柎 鞛堦卑雮� 鞝滉车霅橃 鞎婌晞 瓿奠嫓臧� 鞝滍暅霅╇媹雼�.
R茅sum茅 du Formulaire 144 pour Avidity Biosciences (RNA) : Le d茅p么t signale une proposition de vente de 30,914 actions ordinaires via Morgan Stanley Smith Barney LLC sur le NASDAQ, pour une valeur marchande totale de $1,182,769.64, pr茅vue pour le 08/06/2025. Les titres ont 茅t茅 acquis en tant que Performance Stock Units aupr猫s de l'茅metteur le 12/17/2024 (quantit茅 30,914 ; date de paiement indiqu茅e : 12/17/2024 ; nature du paiement : N/A). Le d茅p么t indique "Rien 脿 signaler" pour les titres vendus au cours des trois derniers mois. Plusieurs champs d'identification et de notification du d茅clarant (CIK, nom du contact de soumission, date de l'avis) sont vides ou non fournis dans le document, ce qui limite la divulgation.
Form-144-Zusammenfassung f眉r Avidity Biosciences (RNA): Die Einreichung meldet einen geplanten Verkauf von 30.914 Stammaktien 眉产别谤 Morgan Stanley Smith Barney LLC an der NASDAQ mit einem Gesamtmarktwert von $1,182,769.64, vorgesehen f眉r den 08/06/2025. Die Wertpapiere wurden am 12/17/2024 als Performance Stock Units vom Emittenten erworben (Anzahl 30,914; Zahlungstag angegeben: 12/17/2024; Art der Zahlung: N/A). Die Einreichung vermerkt "Nichts zu berichten" f眉r in den letzten drei Monaten verkaufte Wertpapiere. Mehrere Identifikations- und Benachrichtigungsfelder des Meldenden (CIK, Name des Einreichungskontakts, Datum der Mitteilung) sind im Dokument leer oder fehlen, was die Offenlegung einschr盲nkt.
FAQ
What does the Form 144 for Avidity Biosciences (RNA) disclose?
When were the shares to be sold acquired for Avidity (RNA)?
Does the Form 144 report any sales of Avidity (RNA) securities in the past three months?
Who is the broker listed for the proposed sale in the Avidity (RNA) filing?
Are filer identity and notice date provided in this Form 144 for RNA?
